Researchers found no detectable levels of semaglutide in breast milk, suggesting minimal risk to breastfed infants, but highlighted the need for monitoring maternal nutrition and milk production.
Amylyx considers scrapping ALS drug following Phase III flop
Share this article Amylyx will spend the next eight weeks reviewing the data with the FDA and ALS community. Image credit: Shutterstock / David Herraez